Sanofi Pasteur, KaloBios Get Fast-Track Designation for Possible Candidate for Pseudomonas Aeruginosa Protection

Sanofi Pasteur, a division of Sanofi (NYSE:SNY) and KaloBios Pharmaceuticals (NASDAQ:KBIO) announced that the United States FDA has awarded them the Fast-Track designation for the investigation of KB001A, an antibody fragment that will protect medically ventilated patients against pneumonia caused by Pseudomonas aeruginosa.

As quoted in the press release:

Under the terms of the current agreement, Sanofi Pasteur has worldwide rights to KaloBios’ KB001A technology for all disease indications related to Pa infections, except cystic fibrosis and bronchiectasis, the rights in which were retained by KaloBios, and Sanofi Pasteur has the option to obtain at a later date.

Click here to read the full Sanofi (NYSE:SNY) and KaloBios Pharmaceuticals (NASDAQ:KBIO) press release.